SAFETY AND EFFICACY OF N-ACETYLCYSTEINE IN HOSPITALIZED PATIENTS WITH HIV-ASSOCIATED TUBERCULOSIS: AN OPEN-LABEL, RANDOMIZED, PHASE II TRIAL (RIPENACTB STUDY).

Safety and efficacy of N-acetylcysteine in hospitalized patients with HIV-associated tuberculosis: An open-label, randomized, phase II trial (RIPENACTB Study).

Despite the availability of effective antimicrobials, tuberculosis (TB) is still a serious health threat.Mortality is even higher in people living with HIV who are diagnosed with TB.New therapies are needed to shorten the time required to cure TB and decrease fatality rates in this population.N-acetylcysteine (NAC) is a glutathione precursor and ha

read more


Retrieving Historical Cases of Aujeszky’s Disease in Sicily (Italy): Report of a Natural Outbreak Affecting Sheep, Goats, Dogs, Cats and Foxes and Considerations on Critical Issues and Perspectives in Light of the Recent EU Regulation 429/2016

GLOSSY LIPSTICK NUDE RAIN #504 Aujeszky’s disease is caused by Suid alphaherpesvirus 1, and its main reservoir host is the pig.However, other species are also susceptible.Infection with this virus causes a severe neurological clinical picture named Aujeszky’s disease, usually accompanied by itching and death a few days after the onset of sympto

read more

Outcomes of a Physician Survey on the Type, Progression, Assessment, and Treatment of Neurological Disease in Mucopolysaccharidoses

The mucopolysaccharidosis (MPS) disorders are a group of rare, inherited lysosomal storage disorders.In each of the 11 MPS (sub)types, deficiency in a specific lysosomal enzyme (1 of 11 identified enzymes) leads to accumulation of Tweed Caps glycosaminoglycans, resulting in cell, tissue, and multi-organ dysfunction.There is great heterogeneity in t

read more